sub:assertion {
d:DB01164 dv:ddi-interactor-in dr:DB01164_DB01212 .
d:DB01212 dv:ddi-interactor-in dr:DB01164_DB01212 .
dr:DB01164_DB01212 dcterms:identifier "drugbank_resource:DB01164_DB01212" ;
dcterms:title "DDI between Calcium Chloride and Ceftriaxone - Calcium Salts (Intravenous) may enhance the adverse/toxic effect of ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Calcium Chloride and Ceftriaxone - Calcium Salts (Intravenous) may enhance the adverse/toxic effect of ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion. [drugbank_resource:DB01164_DB01212]"@en .
}